Trand

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trand

What is Trand? (Tranexamic Acid)

Property Description
Active Ingredient Tranexamic Acid
Form Tablet (oral), Solution (intravenous injection)
Pharmacological Class Antifibrinolytic Agent
General Purpose To prevent the breakdown of blood clots
Origin Synthetic derivative (lysine analogue)

What Type of Medicine is Trand and What is its Active Composition?

Trand is a single-ingredient medicine classified as an antifibrinolytic agent, and its active substance is Tranexamic Acid. This drug belongs to the broader hematologic agent class, meaning it influences the components and functions of the blood system. Tranexamic Acid is a synthetic derivative designed to mimic the structure of the naturally occurring amino acid lysine, distinguishing it from natural compounds. This compound is characterized by its stabilizing effect on fibrin clots. Its composition includes the active Tranexamic Acid component alongside solid excipients for the tablet form or a sterile aqueous solution for the injectable form.


How is Trand Classified by its General Purpose?

The primary general purpose of Trand is to help control or reduce excessive bleeding by preventing the premature breakdown of existing blood clots. It acts through a mechanism that stabilizes fibrin clots—the body’s essential meshwork for stopping blood loss—by reversibly inhibiting the enzymatic process known as fibrinolysis. This mechanism is utilized in managing major hemorrhage and excessive blood loss. By competitively inhibiting the activation of the clot-dissolving enzyme plasmin, the medicine ensures that the fibrin matrix of the clot remains intact and secure longer, contributing to effective blood loss control.


In What Forms is the Drug Trand Available?

Trand is available as both an oral dosage form, typically a film-coated tablet, and a solution for intravenous administration, covering both non-acute and acute medical needs. The oral tablet provides a systemic option for ongoing management, while the solution for injection is administered via the parenteral route, allowing for immediate, direct delivery into the bloodstream. This flexibility in pharmaceutical preparations ensures the medicine can be used for both longer-term management and critical intervention.

Regulatory References

  1. NIH MedlinePlus
  2. World Health Organization (WHO)
  3. WHO Essential Medicines List

What side effects are possible with Trand?

Possible side effects and safety information

Official regulatory documents classify the potential adverse reactions of Tranexamic Acid (Trand) into categories based on frequency and affected body system. The most Common side effects listed are generally related to the Gastrointestinal System, including nausea, vomiting, and diarrhea. Uncommon reactions may involve the skin, such as allergic skin reactions or rash.


Serious Adverse Reactions and Safety Constraints

The safety profile highlights a few rare but clinically significant adverse reactions. Serious events documented in regulatory sources primarily involve the Vascular System, including the risk of thromboembolic events (blood clots, such as deep vein thrombosis and pulmonary embolism). Effects on the Nervous System include the potential for convulsions (seizures), particularly noted following higher doses or rapid intravenous administration. Additionally, visual disturbances, including impaired color vision, are documented as rare events.


Population-Specific Safety and Limitations

Official labeling contains specific safety constraints. The medicine is contraindicated in individuals with active venous or arterial thrombosis and certain bleeding conditions, such as subarachnoid hemorrhage. For patients with renal impairment, the dose must be adjusted due to the risk of accumulation, and the medicine is strictly contraindicated in cases of severe impairment. Furthermore, the official label explicitly mandates that the medicine must not be administered via routes other than intravenous due to the documented risk of severe neurological and fatal events.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information for Trand

This section describes the officially documented manifestations of Trand (Tranexamic Acid) overdose and the actions mandated by regulatory authorities.


Documented Clinical Manifestations and Outcomes

Overdose may present with systemic clinical manifestations, including severe gastrointestinal symptoms such as nausea, vomiting, and diarrhea. Cardiovascular signs, like hypotension (low blood pressure) and orthostatic symptoms, have been documented. Central nervous system effects may involve convulsions, visual impairment, and changes in mental status.

Serious outcomes related to administration error have been documented, specifically cardiac arrhythmias and paraplegia associated with the inadvertent neuraxial (spinal) injection of the solution. The risk of arterial and venous thromboembolism is also a key regulatory concern in the context of overdose.


Emergency Actions and Supportive Measures

Regulatory documents state that patients must seek immediate medical attention and should contact a Poison Control Centre or hospital emergency department upon suspicion of overdose. The prescribed management approach is symptomatic and supportive treatment; no specific antidote is known for Tranexamic Acid overdose. Officially documented supportive measures include considering the use of gastric lavage and activated charcoal.


Population-Specific Overdose Note

Patients with renal insufficiency face a risk of drug accumulation due to impaired clearance, which can increase the potential for toxicity and requires dosage adjustments to mitigate this risk, as noted in official prescribing information.

Therapeutic Uses of Trand

What Trand Treats: Main Uses and Benefits

The medicine is utilized for managing blood loss across several therapeutic areas.

Trand is primarily applied across domains where additional symptomatic support is needed to address symptoms related to heightened physiological activity that manifest as excessive bleeding. The medication is relevant for conditions such as heavy menstrual bleeding (menorrhagia), hemorrhage following childbirth, and bleeding associated with major trauma or invasive surgical procedures. It is also considered relevant for managing bleeding risks in patients with certain conditions like hemophilia and for symptoms associated with acute attacks of hereditary angioedema.

“The medication is commonly used when short-term symptomatic assistance is needed to help manage excessive blood flow.”

Applied in situations involving heightened physiological stress, it supports the patient during difficult episodes by assisting with reducing the volume of blood lost and contributing to easing the overall symptom burden. This supportive relief helps maintain a sense of stability when symptoms are more noticeable.


Quick Fact: Symptomatic Support for Bleeding


Eligibility and Restrictions for Use

Who Can and Cannot Use Trand?

Eligibility for Trand (Tranexamic Acid) is strictly defined by regulatory authorities and is determined primarily by the patient's risk of blood clotting and physiological status.


Absolute Contraindications

The medicine is contraindicated (must not be used) in patients with active thromboembolic disease, a history of thrombosis or thromboembolism, or an intrinsic risk of thrombosis, according to FDA and EMA labeling. Trand is also strictly contraindicated in cases of severe renal impairment and in patients with a history of convulsions.

Age and Physiological Restrictions

Population Group Eligibility Status (Regulatory Wording)
Pediatrics (Oral) Safety and efficacy not established for children under 12 years.
Postmenopausal Women Not indicated for use (Oral form).
Pregnancy Not recommended during the first trimester.
Lactation Not recommended due to excretion in human milk.

Conditional Use

Eligibility is restricted for patients with mild to moderate renal impairment, who require a mandatory dose adjustment to prevent drug accumulation. Use is also restricted until the cause of irregular menstrual bleeding is established. The oral form is contraindicated in women using combined hormonal contraception.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Documented Interaction Patterns

The official interaction profile for Tranexamic Acid is primarily defined by pharmacodynamic effects and absolute restrictions detailed in regulatory documents. Co-administration with combined hormonal contraceptives (including oral tablets, patches, and rings) is strictly contraindicated due to a documented increase in the risk of serious thromboembolic events.

Restrictions and Required Cautions

Interaction constraints also apply to other medicines that influence blood clotting. Use with prothrombotic medical products, such as Factor IX Complex Concentrates or Anti-Inhibitor Coagulant Concentrates, should be avoided because this combination can result in a further elevated risk of thrombosis. Conversely, the antifibrinolytic effect of Tranexamic Acid may be antagonised if co-administered with thrombolytic drugs (like Alteplase).

The regulatory label notes a potential increase in the risk of bleeding when the medicine is used concurrently with Chlorpromazine. Furthermore, the intravenous formulation is contraindicated for use via neuraxial routes (e.g., epidural or intrathecal injection).

Administration and Clearance Considerations

The oral form of the medicine may be administered with or without food. For patients with impaired renal function, a population-specific consideration exists: reduced drug clearance leads to a documented potential for drug accumulation, requiring formal recognition of this reduced clearance.

Mechanism of Action

Molecular Mimicry and Competitive Inhibition of Lysis

The primary mechanism involves Tranexamic Acid acting as a lysine analogue, a molecule designed to mimic the amino acid lysine. This allows it to competitively bind to the lysine-binding sites (LBSs) on the circulating protein plasminogen. By occupying these sites, Trand prevents plasminogen and active plasmin from accessing and degrading the protein meshwork of the clot.

Stabilizing the Fibrinolytic Cascade

This competitive blockage interrupts the entire fibrinolytic system, the pathway responsible for dissolving blood clots. By preventing the enzymatic attack on the fibrin matrix, the drug results in the prolonged maintenance of the clot's structural integrity, promoting a stable hemostatic plug. This systemic effect maintains the integrity of the coagulation product.

Mechanistic Constraints and Secondary Modulations

The core antifibrinolytic action is dependent on a high initial rate of fibrinolysis, characteristic of the period immediately following clot formation. At high concentrations, the molecule can also exhibit an off-target effect by acting as an antagonist of inhibitory GABAA receptors in the central nervous system. Separately, the inhibition of the plasmin system also modulates the attenuation of inflammatory cascades that govern localized fluid accumulation.

Dosage and Administration Information

Administration and Official Dosing Guidelines

Trand (Tranexamic Acid) must be administered according to specific procedural constraints. The medicine is available for both oral and intravenous (IV) administration, with the intramuscular route being prohibited. Dosing is defined by the route and the patient's physiological status.


Official Usage Protocol

Administration Scope Specification Details
Route of Administration Oral (tablet) and Intravenous (IV) injection/infusion.
Standard Dosing Schedule Oral administration is typically 1,300 mg three times daily (TID). IV doses range from 500 mg to 1,000 mg per dose or a weight-based dose of 10 mg/kg.
Timing and Frequency Oral tablets may be taken with or without food. Administration is usually TID and is often time-limited, restricted to a maximum of five consecutive days in a cycle.
Special Conditions The oral tablet must be swallowed whole and not crushed. IV injection requires a slow infusion rate (e.g., not exceeding 1 mL/minute) and must not be mixed with blood or penicillin-containing solutions.
Adjustments Dose reduction is mandatory for patients with renal impairment. Adjustments are based on the measured serum creatinine level.

Connection to the Official Use Protocol

These instructions establish a protocol that governs the use of Trand. The framework dictates precise administration methods, such as the need to preserve the oral tablet's physical integrity and the controlled rate of intravenous delivery, while enforcing adherence to time-limited schedules and mandatory dose adjustments based on renal function.

Recent Clinical Evidence

Research evidence / Overview of studies for Trand


Evidence for Use in Managing Heavy Menstrual Bleeding

Trand was studied for use in research exploring how symptoms change over time in heavy menstrual bleeding, a condition characterized by fluctuating or episodic manifestations. The core evidence comes from numerous Randomized Controlled Trials (RCTs) and Systematic Reviews that included adult premenopausal women. These studies monitored outcomes related to physical discomfort and daily functioning or activity level, using quantitative measurements of blood loss.

Studies conducted during periods of increased symptom activity described patterns observed in the measured blood loss. Research highlights changes measured during the study period when compared to control groups receiving a placebo or other standard care options. These findings help contextualize how patients reported their experience related to managing blood flow across observed populations. The evidence contributes to understanding symptom patterns during defined cycles.

While the evidence contributes to understanding short-term symptom patterns, the follow-up durations were typically limited to around six menstrual cycles. Therefore, long-term effects are not fully established regarding the use of Trand over many years. Additionally, data for certain groups, such as those with specific underlying gynecological conditions, may be limited and heterogeneous compared to the general study population.


Evidence for Use in Acute Major Hemorrhage (Trauma and Childbirth)

Research examined the use of Trand in critical situations involving acute or disruptive episodes of bleeding, particularly following major trauma and postpartum hemorrhage (PPH). The findings are based on exceptionally large-scale, international Multicenter RCTs where the studies focused on episodes where symptoms become more noticeable and monitored outcomes related to physiological strain or stress. Key outcomes monitored were survival (all-cause mortality) and the need for blood transfusions or emergency surgery.

Studies monitored mortality and the requirement for blood product usage in these time-sensitive scenarios. For both trauma and PPH, the evidence indicates that the observed patterns were associated with administration that occurred relatively quickly after the onset of bleeding. Specifically, the data show patterns related to monitored outcomes when the medicine was observed in patients who received it within a few hours of the bleeding event, with differing results compared to later administration.

What remains a subject of ongoing research is the consistency of findings when Trand is administered significantly later than three hours after the bleeding begins; in these cases, the findings were mixed or evidence is limited.


Evidence for Use in Surgical Blood Loss Reduction

Trand was studied for its use in managing blood loss associated with major invasive surgical procedures, such as hip, knee, or cardiac operations. This evidence landscape is supported by a robust collection of RCTs and numerous large Meta-analyses. Research examined outcomes reflecting episodic or acute changes in blood volume, with studies monitoring total measured blood loss during and immediately after the operation, as well as the risk of requiring allogeneic blood transfusion.

The large volume of trials reported a consistent pattern related to lower measured blood loss and a reduced need for blood transfusions in the groups receiving Trand, a pattern that was observed in some studies across a wide range of surgical settings. This research provides insight into short-term changes during the immediate perioperative period.


What Research Gaps and Uncertainties Remain

Studies help show what has been observed so far, but certain areas require further research. The evidence highlights what is known and what is still uncertain about Trand. Key uncertainties include the need for more robust data regarding the effects of Trand when administration is delayed beyond three hours in major hemorrhage settings. The lack of comprehensive, dedicated research tracking long-term effects and durability of response across all indications over multiple years, and the fact that optimal dosing and administration protocols still vary across different surgical disciplines, suggesting that research is ongoing to standardize the most effective methods.

Key Studies & References

  1. Tranexamic Acid for the Treatment of Postpartum Haemorrhage: An International Randomised, Double Blind, Placebo Controlled Trial (WOMAN Trial)
  2. Label: TRANEXAMIC ACID tablet, film coated (FDA/DailyMed)
  3. PROPOSAL FOR THE INCLUSION OF TRANEXAMIC ACID (ANTI-FIBRINOLYTIC – LYSINE ANALOGUE) IN THE WHO MODEL LIST OF ESSENTIAL MEDICINES (2010)

Frequently Asked Questions (FAQ)

Common questions about Trand (FAQ)

Q: Is Trand a common medicine, or is it a new one?

Official sources note that the active ingredient, Tranexamic Acid, is included on the World Health Organization's Model List of Essential Medicines. This global recognition is used to contextualize its role in managing certain conditions, indicating it is not a newly introduced medication.

Q: How quickly can a person expect to notice the effects of Trand?

Pharmacological data describes the onset of action as generally prompt following administration. Blood levels are described as reaching their peak within a few hours after taking an oral dose.

Q: Does Trand cause weight gain or weight loss?

Official regulatory documents do not list weight gain or weight loss as a common or uncommon side effect of this medicine. The official information is purely descriptive of reported adverse effects.

Q: Is it normal to feel tired or dizzy after starting Trand?

Official safety documents indicate that dizziness is a potential side effect. However, fatigue or feeling overly tired is not typically listed among the most commonly reported adverse reactions for this medicine.

Q: Will Trand interact with common over-the-counter pain relievers?

The regulatory label specifies warnings for medicines that influence blood clotting, such as prothrombotic or thrombolytic drugs. While specific interactions with all common over-the-counter pain relievers are not listed, the official documentation provides an informational profile of known drug-drug interactions.

Q: Are there any specific foods I should avoid while using Trand?

Official information indicates that the oral tablet may be taken with or without food. There are no specific foods or beverages required to be avoided, as formal food interactions are not described in the regulatory documentation.

Q: What age group is Trand usually prescribed to?

The oral form is primarily indicated for use in adult premenopausal women for its approved use. Safety and effectiveness are not established for children under 12 years of age.

Q: How long do most people need to stay on Trand?

For its indicated uses, the oral tablet is typically intended for time-limited administration. For example, in the management of heavy menstrual bleeding, administration is restricted to a maximum of five consecutive days per menstrual cycle.

Q: Is Trand a medication that requires long-term use?

For its approved uses, the medicine is typically intended for short-term or time-limited administration. Research evidence available today suggests that the effects of using the medicine over many years are not fully established.

Q: Is there a generic version of Trand available?

Yes, the active ingredient, Tranexamic Acid, is widely available. It is sold as generic products in both oral tablet and intravenous (IV) solution formulations.

Q: Does Trand affect blood pressure?

Official safety information notes that low blood pressure (hypotension) has been reported as a potential side effect. This is particularly noted in regulatory warnings when the intravenous formulation is administered too rapidly.

Q: Does Trand interact with caffeine?

Official drug interaction documentation does not list any specific warning or contraindication regarding the concurrent use of the medicine with caffeine.

Q: Is Trand a cure for the condition it treats?

The medicine is classified as an antifibrinolytic agent, meaning it helps to control or reduce excessive bleeding. Regulatory documents describe it as a management tool and not as a cure for any underlying medical condition.

Q: Does the time of day I take Trand matter?

The oral tablets are typically administered three times daily (TID). The official instructions emphasize maintaining a consistent dosing schedule throughout the day for the designated duration, rather than a specific time of day like morning or night.

Q: What type of healthcare provider typically prescribes Trand?

Given its uses in surgical settings, trauma, and specific gynecological conditions, the medicine is commonly prescribed or administered by gynecologists, surgical specialists, or emergency medical teams.

Q: What kind of monitoring or tests are required while taking Trand?

Regulatory documents describe the need for periodic testing of renal function (kidney function) and ocular examination (eye exam) for patients on prolonged treatment, due to safety concerns about vision disturbances.

Q: Does Trand cause liver problems?

Liver problems are not listed among the common side effects of this medication. However, rare adverse events sometimes observed in post-marketing reports include elevation of liver enzymes, which can be a sign of changes in liver function.

Q: Is the long-term safety profile of Trand well-established?

Research evidence indicates that long-term safety data regarding the use of the medicine over many years is not fully established. This finding is used to contextualize the current scope of the medicine's use.

Q: Why is Trand not recommended for people with a specific health history?

The medicine is strictly contraindicated (must not be used) in patients with a history of certain conditions, such as active blood clots or convulsions (seizures). This is due to the documented risk of severe thromboembolic events and increased seizure risk, respectively, as described in official labeling.

Q: Is Trand safe to take with herbal supplements like St. John's Wort?

Official drug interaction documentation does not typically include comprehensive information on all herbal supplements. Specifically, there is no formal safety classification provided in regulatory documents for the use of the medicine with St. John's Wort.

Q: Can older adults use Trand?

Regulatory labeling does not contain specific contraindications based on age alone for the general older adult population. However, dose adjustments are mandatory for all patients with reduced renal function (impaired kidneys), a condition which is more common in older adults.

Q: Is Trand considered a controlled substance?

No, the active ingredient, Tranexamic Acid, is not classified as a federally controlled substance by drug control agencies.

Q: Are there different names or brands for the same drug as Trand?

Yes, the active ingredient, Tranexamic Acid, is marketed and sold under various brand names around the world. These different brands all contain the same active pharmaceutical ingredient.

Q: Are the side effects of Trand generally serious?

Official documentation lists a high frequency of common side effects, such as gastrointestinal upset, which are generally non-serious. The label also documents a lower frequency of rare but potentially serious adverse events, such as blood clots or convulsions.

Q: What are the signs of a serious allergic reaction to Trand?

Serious allergic reactions are documented as rare events. Signs to watch for include swelling of the face, tongue, or throat, and difficulty breathing. Official labeling documents that these symptoms require immediate medical attention.

Q: Does alcohol change the effect of Trand in the body?

Official regulatory documents do not list a specific interaction warning or contraindication for moderate alcohol consumption with this medicine.

Q: Can Trand affect my ability to drive or operate machinery?

Official labeling documents that due to the documented potential for side effects like dizziness and visual disturbances, patients should be cautious when driving or operating machinery.

Q: Can Trand be crushed or cut?

The official administration instructions for the oral tablet state that it must be swallowed whole and should not be crushed or cut.

Q: What is the half-life of Trand in the body?

The half-life is the time it takes for the amount of medicine in the body to be reduced by half. Pharmacological studies describe the half-life of the medicine as approximately three hours following intravenous administration.

Q: What happens if I stop taking Trand suddenly?

Since the medicine is typically used for the time-limited management of acute or excessive bleeding, stopping it may be associated with a potential return of the bleeding symptoms it was being used to address.

Q: What should I do if I miss a dose of Trand?

Official patient information usually advises taking the missed dose as soon as it is remembered. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped, and the regular schedule resumed.

How should Trand be stored and disposed of?

How to Store and Dispose of Trand?

The official regulatory guidelines define specific conditions for storing and disposing of Trand (Tranexamic Acid).

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C) [FDA Labeling].
Protection Keep away from excessive heat, moisture, and direct light; Do not freeze [TGA Labeling].
Container Keep in the original, tightly closed container [FDA Patient Information].
Child Safety Store the medicine out of the reach of children [FDA Patient Information].

Handling and Disposal

The injection solution is supplied as a single-dose product, and any unused portion must be discarded [EMA SmPC]. Disposal of expired or unused Trand and its waste material must be conducted in accordance with local requirements for pharmaceutical waste [EMA SmPC].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trand found in:

A-Z Index: